• Undertaking a 1-for-4 pro-rata accelerated non-renounceable entitlement offer to raise ~A$145.8 million
• Funds will enable PYC to generate human safety and efficacy data for all three clinical-stage assets and progress a fourth drug candidate into human trials
• PYC Chairman Alan Tribe intends to subscribe for $35 million in new shares

PYC Therapeutics Ltd (ASX:PYC) is a drug development company with three clinical-stage assets, each of which has the potential to become the standard of care in areas of high unmet patient need (markets worth $1-$10 billion per annum). The company is undertaking a 1-for-4 pro-rata accelerated non-renounceable entitlement offer at an offer price of $1.25 per share to raise approximately A$145.8 million. The offer comprises an accelerated institutional component and a retail component for eligible shareholders in Australia and New Zealand. PYC Chairman Alan Tribe intends to subscribe for $35 million in new shares. Successful completion of the offer will enable PYC to generate human safety and efficacy data for all three of its clinical-stage assets as well as progressing a fourth drug candidate with market-leading potential into human trials.